Australia's Garvan Institute is teaming up with startup E-Nome to explore how secure storage of personal genomic records could support medical research.
The Garvan Institute's Genome.One plans to expand to a network of general practitioners, the Australian Financial Review reports.
The two firms are offering a combined genetic disease risk and pharmacogenomic analysis that covers 49 conditions and about 220 medications.
A new Australian service offers whole-genome sequencing and a health assessment, the Sydney Morning Herald reports.
An Australian team has sequenced and mapped the genome of a prostate cancer tumor, as the Australian Financial Review reports.
The reference bank is a sub-project of the Sydney Genomics Collaborative, and will be one of the world's largest publicly available genome banks of older healthy individuals.
The company's Irys genome mapping technology provides researchers with a non-sequencing-based tool that is essential for studying structural variation.
A team from Radboud University in the Netherlands performed a new detailed and transparent cost analysis for sequencing based on both static costs, and factors that may differ from institution to institution.
The Sydney-based genomics center is implementing diagnostic sequencing pipelines and figuring out best practices for incorporating genomics into healthcare.
The current arrangement builds on an existing agreement signed last year that allowed Garvan to use DNAnexus' platform for its genomics activities.
University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.
A new study of a β-thalassemia gene therapy appears promising, according to NPR.
In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.
Futurism writes that gene doping could be the next generation of cheating in sports.